InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (2 ops.)
Explore the full record of transactions filed by Sethuraman Natarajan, President, Research & Develop.. Officer active across 1 companies, notably Entrada Therapeutics, Inc.. In total, 3 disclosures have been recorded. Total volume traded: €682k. The latest transaction was filed on 4 May 2026 — Cession. Regulator: SEC (Form 4). All data is free.
Declarations3 total
US$341,09825,907 shares@ US$13.16620.14% mcap100.0% of flow
Common Stock
SEC:0001873394-26-000003·
€341,09825,907 shares@ €13.16620.14% mcap50.0% of flow
Common Stock
SEC:0001873394-26-000003:0·
011,588 shares0
Common Stock
SEC:0001104659-22-030008:0·
3 of 3 declarations
About Sethuraman Natarajan
Sethuraman Natarajan is President of Research & Development and Chief Scientific Officer at Entrada Therapeutics, Inc. He is responsible for leading the company's research and development operations. With extensive experience in the biopharmaceutical sector, Sethuraman plays a key role in innovation and developing new treatments to meet patient needs.
